Oscar Health reported net income attributable to the company of $167.3m for the third quarter of 2026, against a net loss of $137.5m a year earlier. Earnings from operations were $178.0m, against a loss of $129.3m. In its 5 November results release, the company said the improvement came mainly from better underwriting.

The medical loss ratio fell to 84.0% from 88.5%, which Oscar attributed mainly to disciplined pricing. Favourable prior-period reserve development was smaller, at $42m against $84m a year earlier. The SG&A expense ratio fell to 14.0% from 17.5%. For the first nine months, the medical loss ratio was 78.1% and net income was $1.21bn.

Total revenue rose to about $5.1bn from $3.0bn on rate increases and more members. It included a $250m benefit from updated risk adjustment estimates, which Oscar linked to its members' risk scores relative to the market and to market morbidity that was modestly better than expected. Effectuated membership reached 2.69 million at 30 September, up from 2.12 million a year earlier.

Oscar raised its full-year 2026 outlook for earnings from operations to $850m-$950m, from $600m-$800m. It now expects a medical loss ratio of 80.5%-81.5% and revenue of $19.0bn-$19.3bn. Among its listed risks are the expiry of the enhanced premium tax credits and new program-integrity rules for the ACA market.

Read the source

Oscar Health, Inc. (SEC Form 8-K) · Company · 5 Nov 2026. This is an original brief based on the linked publication. Company statements and forecasts are attributed to their source.

Oscar Health, Inc. (SEC Form 8-K) ↗